An Open-Label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC47, a New Vaccine Against Streptococcus Pneumoniae, in Healthy Subjects.

Trial Profile

An Open-Label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC47, a New Vaccine Against Streptococcus Pneumoniae, in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2014

At a glance

  • Drugs IC 47 (Primary) ; Aluminium hydroxide
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Intercell
  • Most Recent Events

    • 28 Apr 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 28 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Feb 2010 Results reported by Intercell.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top